» Articles » PMID: 32873569

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma

Abstract

Purpose: Chromosomal instability is a hallmark of cancer that results in broad and focal copy-number alterations (CNAs), two events associated with distinct molecular, immunologic, and clinical features. In hepatocellular carcinoma (HCC), the role of CNAs has not been thoroughly assessed. Thus, we dissected the impact of CNA burdens on HCC molecular and immune features.

Experimental Design: We analyzed SNP array data from 452 paired tumor/adjacent resected HCCs and 25 dysplastic nodules. For each sample, broad and focal CNA burdens were quantified using CNApp, and the resulting broad scores (BS) and focal scores (FS) were correlated with transcriptomic, mutational, and methylation profiles, tumor immune composition, and clinicopathologic data.

Results: HCCs with low broad CNA burdens (defined as BS ≤ 4; 17%) presented high inflammation, active infiltrate signaling, high cytolytic activity, and enrichment of the "HCC immune class" and gene signatures related to antigen presentation. Conversely, tumors with chromosomal instability (high broad CNA loads, BS ≥ 11; 40%), displayed immune-excluded traits and were linked to proliferation, dysfunction, and DNA repair. Candidate determinants of the low cytotoxicity and immune exclusion features of high-BS tumors included alterations in antigen-presenting machinery (i.e., HLA), widespread hypomethylation, and decreased rates of observed/expected neoantigenic mutations. High FSs were independent of tumor immune features, but were related to proliferation, dysfunction, and progenitor cell traits.

Conclusions: HCCs with high chromosomal instability exhibit features of immune exclusion, whereas tumors displaying low burdens of broad CNAs present an immune active profile. These CNA scores can be tested to predict response to immunotherapies.

Citing Articles

Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.

Eghbali S, Heumann T Cancers (Basel). 2025; 17(2).

PMID: 39858016 PMC: 11764197. DOI: 10.3390/cancers17020236.


Genomic instability as a driver and suppressor of anti-tumor immunity.

Requesens M, Foijer F, Nijman H, de Bruyn M Front Immunol. 2024; 15:1462496.

PMID: 39544936 PMC: 11562473. DOI: 10.3389/fimmu.2024.1462496.


Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Pique-Gili M, Andreu-Oller C, Mesropian A, Esteban-Fabro R, Barcena-Varela M, Ruiz de Galarreta M JHEP Rep. 2024; 6(11):101212.

PMID: 39524206 PMC: 11550205. DOI: 10.1016/j.jhepr.2024.101212.


Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.

Xu Z, Jiang W, Liu L, Qiu Y, Wang J, Dai S Cancer Immunol Immunother. 2024; 73(5):95.

PMID: 38607586 PMC: 11014826. DOI: 10.1007/s00262-024-03681-x.


Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response.

Zhang W, Zhu Y, Liu H, Zhang Y, Liu H, Adegboro A NPJ Precis Oncol. 2024; 8(1):77.

PMID: 38538696 PMC: 10973470. DOI: 10.1038/s41698-024-00570-5.


References
1.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

2.
Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Gyorffy B . Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Oncoimmunology. 2018; 7(12):e1526613. PMC: 6279340. DOI: 10.1080/2162402X.2018.1526613. View

3.
Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

4.
El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

5.
Chiang D, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B . Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008; 68(16):6779-88. PMC: 2587454. DOI: 10.1158/0008-5472.CAN-08-0742. View